Nyxoah SA Dossier - Source-backed chat

Nyxoah SA

NYXHEuronext Brussels

SectorHealth Care

IndustryHealth Care Equipment

Beta (adjusted)0.98

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $1.33Price as of 1 Oct 2026

Data confidenceNot applicable

Market Cap $135.4M

Shares Outstanding 101.8M diluted

Next Earnings Date5 Nov 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Nyxoah SA is positioned as a highly disruptive challenger in the $3 billion obstructive sleep apnea (OSA) neuromodulation market. Following the FDA approval of its Genio system in August 2025, the company has entered a high-growth commercialization phase in the United States. Genio's unique bilateral, leadless, and battery-free design offers a compelling alternative to standard CPAP therapy and competing unilateral implants. Backed by a newly completed $95 million equity financing and a planned EIB loan draw, Nyxoah has the capital runway to aggressively scale its U.S. sales force and expand its manufacturing footprint in Belgium. While near-term legal overhang from patent disputes with the market leader presents a risk, the massive unmet clinical need and Genio's superior patient-centric profile support a strong growth trajectory.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets3 analysts · as of 18 Aug 2026

Low · most bearish analyst$3.01

Mean target$6.00

High · most bullish analyst$10.96

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

The bear case reflects prolonged legal battles with Inspire Medical Systems resulting in high defense costs or a partial injunction that limits U.S. commercialization. Slower surgeon training, persistent reimbursement friction, or delayed manufacturing scale-up at LégiaPark could depress revenue growth and extend the company's cash burn, forcing further dilutive capital raises.

Base CaseCentral scenario

The base case assumes successful commercial execution of the Genio system in the U.S., with global net revenues reaching the guided range of €36–40 million in fiscal year 2026. Gross margins are expected to recover to 60–62% as production yield issues are resolved, and the company successfully transitions to a U.S.-based CEO to lead its next phase of growth. Patent litigation with Inspire Medical Systems is expected to eventually resolve in a cross-licensing settlement, removing the legal overhang.

Bull CaseUpside scenario

Rapid U.S. commercial adoption of the Genio system following FDA approval, successful transition to a highly experienced U.S.-based CEO, and positive clinical results from the ACCCESS study leading to a CCC label expansion in the U.S., allowing Nyxoah to capture significant market share from the monopoly incumbent.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

FDA approval of the Genio system in August 2025 opens up the massive and highly lucrative U.S. sleep apnea market.
Genio is the only bilateral, leadless, and battery-free hypoglossal nerve stimulation device, offering superior patient comfort and avoiding repeat surgeries for battery swaps.
Strong balance sheet with $95 million in newly raised equity capital and an upcoming $15 million EIB loan tranche to fund U.S. commercialization.
Strategic expansion of Belgian manufacturing capacity with a new 2,000 square meter facility at LégiaPark to support long-term gross margin expansion.

Key Investment Risks

Ongoing patent infringement litigation with market leader Inspire Medical Systems in the U.S. District Court of Delaware.
Execution risk associated with scaling the U.S. commercial team and transitioning to a new U.S.-based CEO.
Near-term gross margin pressure due to production yield issues, though management indicates these have been resolved.
High operational cash burn as the company ramps up selling, general, and administrative expenses to support the U.S. launch.

Thesis Invalidation Triggers

An unfavorable court ruling or preliminary injunction in the Delaware patent lawsuit that halts or severely restricts U.S. sales of the Genio system.
A significant delay or failure in appointing a qualified U.S.-based CEO, disrupting the commercial launch momentum.
Failure to meet the guided fiscal year 2026 global net revenue range of €36–40 million.
Severe delays in the construction or regulatory validation of the LégiaPark manufacturing facility.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.